This article is more than 5 years old. Information may no longer be current.

OSI, PR Pharmaceuticals to collaborate on sustained-release Macugen formulation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT COLLINS, Colo. — A sustained release formulation of an age-related macular degeneration drug is being developed, according to a press release.

PR Pharmaceuticals and OSI Pharmaceuticals are collaborating on the development of a sustained-release formulation of Macugen (pegaptanib sodium), using PR Pharmaceutical’s proprietary encapsulation technology dubbed ProPhase.

Under terms of the agreement, PR Pharmaceuticals will be responsible for developing the formulations and manufacturing the test article for non-clinical and clinical trials; OSI retains the right to manufacture and commercialize any resulting product.

Macugen is currently approved in the United States for the treatment of neovascular AMD and is administered in a 0.3 mg dose once every 6 weeks by intravitreal injection. ProPhase technology reduces injection frequency. It combines approved biodegradable polymers to form controlled release microparticles with a Food and Drug Administration-approved protective shield for the protein, according to PR Pharmaceuticals.